United States Mammography - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the United States mammography market size in 2026 is estimated at USD 1.26 billion, growing from 2025 value of USD 1.15 billion with 2031 projections showing USD 1.96 billion, growing at 9.28% CAGR over 2026-2031.

This report is Segmented by Product Type (Digital Systems, 3-D Breast Tomosynthesis Systems, Analog Systems, and More), Technology (2-D Full-Field Digital, and More), Application (Screening, Diagnostic), End User (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers, Others). The Market Forecasts are Provided in Terms of Value (USD).

United States Mammography Market Trends and Insights

Growing Burden of Breast Cancer

The incidence among women aged 40-49 years increased by 2% annually from 2015 to 2019, prompting the USPSTF to lower the screening age to 40 years. The decision instantly widened the United States mammography market by roughly 20 million newly eligible women and increased demand on facilities already contending with radiologist shortages. Mortality among Black women remains 40% higher than that of White women, spurring inner-city programs to adopt contrast-enhanced mammography that delivers 88.9% sensitivity versus 27.8% for standard 2-D imaging. Workforce gaps estimated at 1,400 unfilled fellowship positions intensify reliance on AI decision support to maintain throughput. Dense breast tissue in up to half of women over 40 strengthens the case for tomosynthesis and photon-counting systems that reveal occult lesions. Together, these epidemiological pressures elevate capital expenditure and reinforce the long-run momentum of the United States mammography market.

Federal Reimbursement for 3-D Tomosynthesis

The Centers for Medicare & Medicaid Services (CMS) instituted national coverage for digital breast tomosynthesis, eliminating the historical USD 50-80 out-of-pocket differential that had suppressed uptake . Commercial insurers quickly mirrored CMS, and today, 95% of privately insured members can access 3-D exams without prior authorization. Parity coincides with compelling clinical proof: DBT lowers callback rates by 41% and improves cancer detection by 29%. Revenue visibility accelerates the replacement of legacy 2-D units, shortening equipment lifecycles from 9 years to nearer 6 years. Providers serving Medicare-dominant catchments in Florida, Arizona, and Pennsylvania are upgrading first, creating a ripple effect that extends to second-tier markets, which are seeking competitive parity.

Radiation-Dose Safety Concerns

DBT exposes patients to 15-25% higher dose than 2-D exams, with a mean glandular dose at 2.04-2.33 mGy versus 1.40-1.89 mGy for FFDM. Patient advocates amplify concerns about cumulative exposure, especially for the newly included 40-year-old cohort, who face decades of annual screening. FDA MQSA inspectors flag dose violations more frequently as facilities increase exam volumes. Manufacturers counter with AI-enhanced reconstruction and photon-counting detectors that deliver sub-2 mGy performance, yet lingering perceptions hinder rapid adoption in children's hospitals and family clinics. Dose anxiety marginally tempers the United States mammography market, although technology improvements are steadily narrowing the gap.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Technology Upgrades
2. Expansion of Breast Density-Notification Laws
3. High Capital & Service Costs of DBT Units

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Digital equipment captured 60.78% of the market in 2025, mirroring the near-complete exit of film units. Yet replacement momentum is shifting toward 3-D tomosynthesis, projected to advance at 9.88% CAGR through 2031 as payers equalize reimbursement and clinical evidence grows. Analog systems primarily remain in isolated clinics; retrofit kits prolong function but steadily lose relevance as regulatory pressure intensifies. Premium contrast-enhanced platforms, validated by SCEMAM, open a differentiated lane for tertiary centers seeking diagnostic superiority. Overall, rising preference for volumetric and contrast imaging is driving growth in the United States mammography market.

The value proposition of digital upgrades combines image clarity, workflow automation, and AI analytics, which reduce reading time by 30-40%. Providers view premium packages as not simple replacements, but rather as competitive assets that attract referrals and justify higher technical fees. As mobile fleets modernize their onboard suites, digital manufacturers enlarge after-market revenues for software licenses and detector swaps, further deepening the United States mammography market.

Full-field digital retains 50.40% share, but photon-counting detectors headline innovation because they pair ultra-high resolution with reduced exposure. Early adopters report sharper microcalcification visualization, translating to fewer false negatives and lower recall rates. AI-guided CAD and triage tools, such as ProFound Detection 4.0, reduce reading time and improve specificity, accelerating AI adoption across the United States mammography market.

3-D tomosynthesis gains reimbursement traction, while Clairity Breast's predictive capability signals a future shift from detection to risk-stratified screening. Vendors embed smart-worklist features that auto-route complex cases to fellowship specialists, easing the radiologist shortage. Integration of cloud deployment secures scalability for multisite chains, underscoring how software differentiation now defines competitive positioning in the United States mammography market.

Complete Report Scope:

• By Product Type
  • Digital Systems
  • 3-D Breast Tomosynthesis Systems
  • Analog Systems
  • Computed-Radiography Retrofit Kits
  • Contrast-Enhanced Mammography Systems
• By Technology
  • 2-D Full-field Digital
  • 3-D / Tomosynthesis
  • Photon-Counting Digital
  • AI-enabled CAD & Image-triage
• By Application
  • Screening
  • Diagnostic
• By End User
  • Hospitals
  • Diagnostic Imaging Centers
  • Ambulatory Surgical Centers
  • Others

List of Companies Covered in this Report:

1. Hologic
2. GE Healthcare
3. Siemens Healthineers
4. Fujifilm Holdings Corp.
5. Canon
6. Carestream Health
7. Konica Minolta
8. Planmed
9. Agfa-Gevaert
10. IMS Giotto
11. Metaltronica
12. iCAD Inc.
13. Delphinus Medical Technologies
14. Sectra
15. Volpara Health
16. ScreenPoint Medical
17. Hitachi
18. Aurora Imaging Technology
19. Dilon Technologies
20. PerkinElmer

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support